- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 249 of 2,219.
| EudraCT Number: 2015-003639-37 | Sponsor Protocol Number: D4198C00003 | Start Date*: 2017-03-28 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma | |||||||||||||
| Medical condition: Adult patients (aged ≥18 years) with histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma who are treatment naive or have tumor progression following prior standard... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003986-25 | Sponsor Protocol Number: ADAMPA | Start Date*: 2017-05-05 | |||||||||||
| Sponsor Name:Instituto de Investigación Sanitaria INCLIVA | |||||||||||||
| Full Title: Impact of self-measurement of blood pressure and self-adjustment of antihypertensive medication in the control of hypertension and adherence to treatment. A pragmatic, randomized, controlled clinic... | |||||||||||||
| Medical condition: Arterial hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-005666-29 | Sponsor Protocol Number: Theta001 | Start Date*: 2015-10-16 | |||||||||||
| Sponsor Name:4D Pharma | |||||||||||||
| Full Title: A Phase 1 randomised, double-blind, placebo-controlled study to assess the safety and tolerability of Bacteroides thetaiotaomicron in young people aged 16 to 18 years with stable Crohn's disease. | |||||||||||||
| Medical condition: Crohn's disease in young persons | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004879-46 | Sponsor Protocol Number: RG_16-123 | Start Date*: 2017-06-15 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL) | |||||||||||||
| Medical condition: Relapsed and refractory T-cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-003039-31 | Sponsor Protocol Number: D1002002 | Start Date*: 2015-08-20 | |||||||||||
| Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd. | |||||||||||||
| Full Title: A Long-Term Study of SM-13496 in Patients with Bipolar I Disorder | |||||||||||||
| Medical condition: Bipolar I depression | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002272-24 | Sponsor Protocol Number: M13-594 | Start Date*: 2016-01-26 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Vi... | |||||||||||||
| Medical condition: Chronic HCV Genotype 3 Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (Completed) SE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-001523-31 | Sponsor Protocol Number: U1111-1181-4107 | Start Date*: 2017-01-30 | |||||||||||
| Sponsor Name:Steno Diabetes Center Copenhagen | |||||||||||||
| Full Title: Effect of liraglutide on vascular inflammation in type-2 diabetes: A randomized, placebo-controlled, double-blind, parallel clinical PET/CT trial | |||||||||||||
| Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002254-20 | Sponsor Protocol Number: 1297.9 | Start Date*: 2017-08-04 | |||||||||||
| Sponsor Name:Boehringer Ingelheim International GmbH | |||||||||||||
| Full Title: VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm,... | |||||||||||||
| Medical condition: moderate to severe chronic plaque psoriasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LV (Completed) HU (Completed) DE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000393-34 | Sponsor Protocol Number: R03003 | Start Date*: 2015-06-01 | ||||||||||||||||
| Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | ||||||||||||||||||
| Full Title: Clinical trial of the investigational medicinal product, local anaesthetic levo-bupivacaine in infants 3 - 6 months post natal age. | ||||||||||||||||||
| Medical condition: Pain relief in infants undergoing surgical repair of bladder exstrophy | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2012-005641-21 | Sponsor Protocol Number: 112148 | Start Date*: 2015-05-26 | ||||||||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
| Full Title: A phase III, open, controlled study to assess the persistence of antibodies after one dose of GlaxoSmithKline Biologicals’ meningococcal serogroup ACWY conjugate vaccine (MenACWY-TT) given intramus... | ||||||||||||||||||
| Medical condition: Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and/or Y | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-003005-41 | Sponsor Protocol Number: CS0866-A-U101 | Start Date*: 2015-07-24 |
| Sponsor Name:Sankyo Pharma Development | ||
| Full Title: A Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of a Compounded 4 mg/mL Olmesartan Medoxomil Suspension (Total Dose 40 mg) and 40 mg Olmesartan Medoxomil Tablets (Beni... | ||
| Medical condition: Not applicable - Healthy Volunteer study | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2011-005913-35 | Sponsor Protocol Number: DB2116132 | Start Date*: 2012-06-27 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
| Full Title: A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily... | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002823-27 | Sponsor Protocol Number: GAVALAGG | Start Date*: 2016-11-17 | |||||||||||
| Sponsor Name:INFECTOPHARM Arzneimittel GmbH | |||||||||||||
| Full Title: Placebo-kontrollierte, multizentrische, randomisierte, doppelblinde Phase III-Studie zur Verbesserung der gastrointestinalen Verträglichkeit einer per-oralen Antibiotikatherapie durch add-on-Gabe v... | |||||||||||||
| Medical condition: Verbesserung der gastrointestinalen Verträglichkeit einer per-oralen Antibiotikatherapie | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004594-41 | Sponsor Protocol Number: 2016-1 | Start Date*: 2017-01-13 | |||||||||||
| Sponsor Name:Jens Børglum | |||||||||||||
| Full Title: Ultrasound-guided Transmuscular Quadratus Lumborum block for elective caesarean section. A double blind, randomized, placebo controlled trial. | |||||||||||||
| Medical condition: Postoperative pain and opioid consumption after elective caesarean section. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001607-80 | Sponsor Protocol Number: 112581 | Start Date*: 2017-11-14 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: An open-label primary vaccination study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis vaccine Poliorix administered as a three-dose primary vacci... | ||
| Medical condition: Healthy volunteers (Poliomyelitis) | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2012-005032-29 | Sponsor Protocol Number: EPP | Start Date*: 2013-09-10 | |||||||||||
| Sponsor Name:Association Bigorre Douleurs | |||||||||||||
| Full Title: Transmucosal Effentora® efficacy and safety for pre-emptive procedural pain treatment in opioid tolerant cancer patients. | |||||||||||||
| Medical condition: Painful procedures requiring analgesia in patients receiving already opioids for their background pain. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-000722-19 | Sponsor Protocol Number: M12-919 | Start Date*: 2016-10-24 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function | |||||||||||||
| Medical condition: Diabetic Nephropathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002932-42 | Sponsor Protocol Number: V501-110-01 | Start Date*: 2016-12-14 |
| Sponsor Name:MSD K.K., a subsidiary of Merck & Co., Inc | ||
| Full Title: A Phase IV Open-label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 ... | ||
| Medical condition: Human Papillomavirus infection | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2017-000246-21 | Sponsor Protocol Number: PP100-001 | Start Date*: 2017-04-25 | |||||||||||
| Sponsor Name:PledPharma AB | |||||||||||||
| Full Title: A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose | |||||||||||||
| Medical condition: The objective of this study is to develop a therapeutic regimen for paracetamol/acetaminophen overdose (POD) where a novel NAC 12hr regime is combined with a superoxide dismutase (SOD) mimetic, PP1... | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001094-16 | Sponsor Protocol Number: PROACT | Start Date*: 2017-08-08 | |||||||||||
| Sponsor Name:South Tees NHS Foundation Trust | |||||||||||||
| Full Title: Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity ... | |||||||||||||
| Medical condition: Prevention of cardiotoxicity | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.